Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis

Alimentary Pharmacology and Therapeutics

Volumn 46, Issue 7, 2017, Pages 657-667

  Zagari, R M ^a   Rabitti, S ^a   Greenwood, D C ^b   Eusebi, L H ^a   Vestito, A ^c   Bazzoli, F ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN 17; PEPSINOGEN; GASTRIN;

ATROPHIC GASTRITIS; BLOOD ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HELICOBACTER PYLORI ANTIBODY SERUM ASSAY; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; META ANALYSIS; OUTCOME ASSESSMENT; PATHOLOGICAL ANATOMY; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PUBLICATION; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; BLOOD; BLOOD EXAMINATION; COST BENEFIT ANALYSIS; DIAGNOSTIC IMAGING; HELICOBACTER INFECTION; HELICOBACTER PYLORI; IMMUNOLOGY; REPRODUCIBILITY; STOMACH TUMOR;

COST-BENEFIT ANALYSIS; GASTRINS; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HEMATOLOGIC TESTS; HUMANS; PEPSINOGEN A; PREVALENCE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS;

EID: 85027148875     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.14248     Document Type: Review

References (57)

1. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. the update Sydney system. International workshop on the histopathology of gastritis. Houston 1994. Am J Surg Pathol. 1996;20:1161-1181.
2. Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012;44:74-94.
3. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection – the Maastricht V/Florence consensus report. Gut. 2017; 66: 6-30.
4. Sugano K, Tack J, Kuipers E, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353-1367.
5. Agréus L, Kuipers EJ, Kupcinskas L, et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol. 2012;47:136-147.
6. Cochrane Collaboration. Diagnostic Test Accuracy Working Group: handbook for DTA reviews. http://srdta.cochrane.org/handbook-dta-reviews.
7. Sipponen P, Ranta P, Helske T, et al. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study. Scand J Gastroenterol. 2002;37:785-791.
8. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529-536.
9. Reitsma JB, Glas AS, Rutjes AW, et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005;58:982-990.
10. Wang F, Gatsonis CA. Hierarchical models for ROC curve summary measures: design and analysis of multireader, multimodality studies of medical tests. Stat Med. 2008;27:243-256.
11. Skrondal A, Rabe-Hesketh S. Generalized latent variable modeling: multilevel, longitudinal, and structural equation models.Boca Raton, FL: Chapman & Hall/CRC; 2004.
12. Väänänen H, Vauhkonen M, Helske T, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol. 2003;15:885-891.
13. Broutet N, Plebani M. Sakarovitch, Sipponen P, Megraud F. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. Br J Cancer. 2003;88:1239-1247.
14. Di Mario F, Moussa AM, Caruana P, et al. “Serological biopsy” in first-degree relatives of patients with gastric cancer affected by Helicobacter pylori infection. Scand J Gastroenterol. 2003;28:1223-1227.
15. Hartleb M, Wandzel P, Walunga M, et al. Non-endoscopic diagnosis of multifocal atrophic gastritis;efficacy of serum gastrin-17, pepsinogens and Helicobacter pylori antibodies. Acta Gastro-Enterologica Belgica. 2004;67:320-326.
16. Ricci C, Vakil N, Rugge M, et al. Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori. Am J Gastroenterol. 2004;99:1910-1915.
17. Pasechnikov VD, Chukov SZ, Kotelevets SM, et al. Possibility of non-invasive diagnosis of gastric mucosal precancerous changes. World J Gastroenterol. 2004;10:3146-3150.
18. Pasechnikov VD, Chucov SZ, Kotelevets SM, et al. Invasive and non-invasive diagnosis of Helicobacter pylori-associated atrophic gastritis: a comparative study. Scand J Gastroenterol. 2005;40:297-301.
19. Germaná B, Di Mario F, Cavallaro LG, et al. Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacter pylori antibodies in the management of dyspeptic patients in primary care. Dig Liver Dis. 2005;37:501-508.
20. Nardone G, Rocco A, Staibano S, et al. Diagnostic accuracy of the serum profile of gastric mucosa in relation to histological and morphometric diagnosis of atrophy. Aliment Pharmacol Ther. 2005;22:1139-1146.
21. Graham DY, Nurgalieva ZZ, El-Zimaity HMT, et al. Non-invasive versus histological detection of gastric atrophy in a Hispanic population in North America. Clin Gastroenterol Hepatol. 2006;4:306-314.
22. Cao Q, Ran ZH, Xiao SD. Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies. J Dig Dis. 2007;8:15-22.
23. Valle Munoz J, Artaza Varasa T, Lopez Pardo R, et al. Serological diagnosis of atrophic gastritis with a combination of pepsinogen I and II, Gastrin-17 and anti-Helicobacter pylori antibodies. Gastroenterol Hepatol. 2007;30:567-571.
24. Koivusalo AI, Pakarinen MP, Kolho KL. Is GastroPanel serum assay useful in the diagnosis of Helicobacter pylori infection and associated gastritis in children? Diagn Microbiol Infect Dis. 2007;57:35-38.
25. De Angelis GL, Cavallaro LG, Maffini V, et al. Usefulness of a serological panel test in the assessment of gastritis in symptomatic children. Dig Dis. 2007;25:206-213.
26. Storskrubb T, Aro P, Ronkainen J, et al. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol. 2008;43:1448-1455.
27. Haj-Sheykholeslami A, Rakhishani N, Amirzargar A, et al. Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis. Clin Gastroenterol Hepatol. 2008;6:174-179.
28. Guariso G, Basso D, Bortoluzzi CF, et al. GastroPanel: evaluation of the usefulness in the diagnosis of gastro-duodenal mucosal alterations in children. Clin Chim Acta. 2009;402:54-60.
29. Agreus L, Storskrubb T, Aro P, et al. Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum level of amidated gastrine-17, pepsinogen I and pepsinogen II in a random adult population. Scand J Gastroenterol. 2009;44:564-570.
30. Ijima K, Abe Y, Kikuchi R, et al. Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. World J Gastroenterol. 2009;15:853-859.
31. Leja M, Kupcinskas L, Funka K, et al. The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopatology. Dig Dis Sci. 2009;54:2377-2384.
32. Melton SD, Genta RM, Souza RF. Biomarkers and molecular diagnostic tests in gastrointestinal tract and pancreatic neoplasms. Nat Rev Gastrenterol Hepatol. 2010;7:620-628.
33. Lombardo L, Leto R, Molinaro G, et al. Prevalence of atrophic gastritis in dyspeptic patients in Piedmont. A survey using the GastroPanel test. Clin Chem Lab Med. 2010;48:1327-1332.
34. Kikuki R, Abe Y, Iijima K, et al. Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high risk of early gastric cancer. Tohoku J Exp Med. 2011;223:35-44.
35. Peitz U, Wex T, Vieth M, et al. Correlation of serum pepsinogens and gastrin-17 with atrophic gastritis in gastroesophageal reflux patients: a matched-pairs study. J Gastroenterol Hepatol. 2011;26:82-89.
36. Nasrollhazadeh D, Aghcheli K, Sotoudeh M, et al. Accuracy and cut-off values of pepsinogen I, II, and gastrin 17 for diagnosis of gastric fundic atrophy: influence of gastritis. PLoS ONE. 2011;6:e26-e957.
37. Bornschein J, Selgrad M, Wex T, Kuester D, Malfertheiner P. Serological assessment of gastric mucosal atrophy in gastric cancer. BMC Gastroenterol. 2012;12:10.
38. Noah Noah D, Okomo Assoumou MC, Eloumou Bagnaka SAF, et al. Assessing GastroPanel serum markers as a non invasive method for the diagnosis of atrophic gastritis and Helicobacter pylori infection. Open J Gastroenterol. 2012;2:113-118.
39. Yakut M, Ormeci N, Erdal H, et al. The association between precancerous gastric lesions and serum pepsinogens, serum gastrin, vascular endothelial growth factor, serum interleukin-1Beta, serum toll-like receptor-4 levels and Helicobacter pylori Cag A status. Clin Res Hepatol Gastroenterol. 2013;37:302-311.
40. Shafaghi A, Mansour-Ghanaei F, Joukar F, et al. Serum gastrin and the pepsinogen I/II ratio as markers for diagnosis of premalignant gastric lesions. Asian Pacific J Cancer Prev. 2013;14:3931-3936.
41. Hosseini M, Amoueian S, Attaranzadeh A, et al. Serum gastrin 17, pespinogen I and pepsinogen II in atrophic gastritis patients living in North-East of Iran. J Res Med Sci. 2013;18:225-229.
42. McNicholl AG, Fornè M, Barrio J, et al. Accuracy of GastroPanel for the diagnosis of atrophic gastritis. Eur J Gastroenterol Hepatol. 2014;26:941-948.
43. Masci E, Pellicano R, Mangiavillano B, et al. GastroPanel test for non invasive diagnosis of atrophic gastritis in patients with dyspepsia. Minerva Gastroenterol Dietol. 2014;60:79-83.
44. Mansour-Ghanaei F, Joukar F, Rajpout Y, Hasandokht T. Screening of precancerous gastric lesions by serum pepsinogen, gastrin-17, anti-Helicobacter pylori and anti-Cag A antibodies in dyspeptic patients over 50 years old in Guilan province, north of Iran. Asian Pacific J Cancer Prev. 2014;15:7635-7638.
45. Nejadi-Kelarijiani F, Roshandel G, Semnani S, et al. Diagnostic values of serum levels of pepsinogens and gastrin-17 for screening gastritis and gastric cancer in a high risk area in Northern Iran. Asian Pacific J Cancer Prev. 2014;15:1733-1736.
46. Tu H, Sun L, Dong X, et al. Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: a longitudinal study. Int J Cancer. 2015;136:425-434.
47. Roman LD, Lukyanchuk R, Sablin OA, et al. Prevalence of H. pylori infection and atrophic gastritis in a population-based screening with serum biomarker panel (GastroPanel) in St. Petersburg. Anticancer Res. 2016; 36: 4129-4138.
48. Pyurveyeva KV, Lapina TL, Ivashkin VT, et al. Serum pepsinogen I, pepsinogen II and gastrin-17 in diagnostics of atrophic gastritis. RZGGK. 2005;3:48-51.
49. Zagari RM, Nicolini G, Casanova S, et al. Diagnosis of atrophic gastritis in the general population based on a combination of three non invasive tests [Abstract]. Gut. 2002;51(Suppl 11):A39.
50. de Korwin JD, Prucha V, Lozniewski A, et al. Non endoscopic diagnosis of atrophic gastritis using the GastroPanel/Gastrosoft [Abstract]. Helicobacter. 2004;9:A561.
51. Cavallaro LG, Merli R, Liatopoulou S, et al. Accuracy of “serologic gastric biopsy” in a cohort of dyspeptic patients [Abstract]. Helicobacter. 2005;10:A503.
52. Di Mario F, Rugge M, Cavestro GM, et al. Usefulness of serum pepsinogens to identify chronic atrophic gastritis [Abstract]. Gastroenterology. 2011;140: (Suppl 1):S318.
53. Goni E, Franceschi M, Scarpignato C, Rugge M, Di Mario F. Relationship between GastroPanel and OLGA in the detection of chronic atrophic gastritis in a primary care setting [Abstract]. UEGJ. 2015;3(5S):A297.
54. Marques-Silva L, Areia M, Elvas L, Dinis-Riberio M. Prevalence of gastric precancerous conditions: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2014;26:378-387.
55. Wang X, Ling L, Li S, et al. The diagnostic value of gastrin-17 detection in atrophic gastritis. A meta-analysis. Medicine (Baltimore). 2016; 95:e3599.
56. Syrjanen K. A panel of serum biomarkers (GastroPanel) in non-invasive diagnosis of atrophic gastritis. Systematic review and meta-analysis. Anticancer Research. 2016;36:5133-5144.
57. Huang YK, Yu JC, Kang WM, et al. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: a systematic review and meta-analysis. PlosOne. 2015;10(11):e0142080.